Cartesian Growth Corporation IV (the “Company”) announced today the pricing of its initial public offering of 25,000,000 units, at a price of $10.00 per unit. The units are expected to commence ...

Cartesian Therapeutics, Inc. RNAC announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of ...

Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

Cartesian Growth Corp. IV stock grades by Barron's. View CGCFU fundamental and sentiment analysis powered by MarketGrader.

Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...

Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell therapies using a drug delivery technology developed by the mRNA therapeutics ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Cartesian Growth Corporation IV (the “Company”) announced today the closing of its initial public offering of 27,500,000 units, including 2,500,000 units pursuant to the partial exercise of the ...